Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPF-CCRT
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
BPF-CCRT is a neoadjuvant concurrent chemoradiation (CCRT) regimen under investigation for locally advanced esophageal squamous cell carcinoma (ESCC). This regimen combines Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), with a standard platinum-fluorouracil (PF) chemotherapy regimen and concurrent radiation therapy. The goal of BPF-CCRT is to enhance treatment response and increase pathological complete response rates in patients with ESCC, particularly given the unsatisfactory outcomes with existing therapies and the role of VEGF-A in prognosis.
- Other names
- neoadjuvant PF-CCRT plus Bevacizumab
02
Targets
Beyond the preview
Go deeper on BPF-CCRT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPF-CCRT.